Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Down 74.3% in January

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the recipient of a significant drop in short interest in January. As of January 15th, there was short interest totalling 117,500 shares, a drop of 74.3% from the December 31st total of 457,500 shares. Based on an average daily trading volume, of 3,580,000 shares, the short-interest ratio is currently 0.0 days. Currently, 0.8% of the shares of the stock are short sold.

Virpax Pharmaceuticals Price Performance

Shares of VRPX stock opened at $0.31 on Friday. The business’s 50-day moving average price is $0.36 and its 200-day moving average price is $0.68. Virpax Pharmaceuticals has a 12 month low of $0.23 and a 12 month high of $5.48.

Analyst Upgrades and Downgrades

Separately, Maxim Group reiterated a “hold” rating on shares of Virpax Pharmaceuticals in a report on Wednesday, October 9th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC bought a new stake in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned 1.17% of Virpax Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 32.23% of the stock is owned by institutional investors and hedge funds.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.